Integrated BioPharma (INBP) AI Stock Analysis

• Market Cap: $11.38M
• Dividend Yield: N/A
• Average Volume (3M): 15.15K
• Price to Earnings (P/E): 17.3
• Beta (1Y): 0.03
• Revenue Growth: 4.72%
• EPS Growth: 55.24%
• Country: US
• Employees: 147
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): <0.01
• Shares Outstanding: 31,059,610
• 10 Day Avg. Volume: 31,065
• 30 Day Avg. Volume: 15,153
• PEG Ratio: 0.02
• Price to Book (P/B): 0.53
• Price to Sales (P/S): 0.20
• P/FCF Ratio: 5.77
• Enterprise Value/Market Cap: 0.44
• Enterprise Value/Revenue: 0.12
• Enterprise Value/Gross Profit: 0.97
• Enterprise Value/Ebitda: 1.72
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: $0.38 ▲(11.18% Upside)

The score is driven primarily by solid financial stability (very low leverage and improving cash flow), which helps offset operating pressure from a steep TTM revenue decline and thin margins. Technicals add modest support with an upward bias (price above key moving averages and positive MACD), while valuation is only fair at ~16.5x earnings without a provided dividend yield.

Positive Factors

Cash Generation

Strong cash generation enhances financial flexibility, allowing for reinvestment in growth opportunities and reducing reliance on external financing.

Leverage Reduction

Reduced leverage strengthens the balance sheet, lowering financial risk and enhancing the company's ability to withstand economic fluctuations.

Profitability Improvement

Improved gross margins indicate better cost management, which can lead to enhanced profitability and competitive pricing strategies over time.

Negative Factors

Low Net Profit Margin

Low net profit margins suggest challenges in converting revenue into profit, potentially impacting long-term profitability and shareholder returns.

Earnings Call Data Absence

The absence of earnings call data limits insights into management's strategic direction and future financial guidance, affecting investor confidence.

Dividend Yield Absence

Lack of dividend yield can make the stock less attractive to income-focused investors, potentially limiting the investor base and affecting stock demand.

Integrated BioPharma Business Overview & Revenue Model

Company Description

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized healthcare providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

How the Company Makes Money

Integrated BioPharma generates revenue through multiple streams, primarily by selling its pharmaceutical and nutraceutical products directly to consumers and through partnerships with healthcare providers and distributors. The company's revenue model includes retail sales, online sales, and wholesale distribution. Additionally, INBP may engage in licensing agreements with other pharmaceutical companies for the development and commercialization of specific products, which can provide significant royalties and milestone payments. Strategic collaborations with research institutions and healthcare organizations also contribute to its earnings by enhancing product development and expanding market reach.

Integrated BioPharma Financial Statement Overview

Summary

Integrated BioPharma demonstrates a solid financial performance with improvements in revenue growth, profitability, and cash flow generation. The reduction in leverage and strong equity position enhance financial stability. However, the company needs to focus on further improving net profit margins to enhance overall profitability.

Income Statement

Integrated BioPharma has shown a modest revenue growth rate of 2.7% in the latest year, recovering from previous declines. The gross profit margin improved to 10.23%, indicating better cost management. However, the net profit margin remains low at 1.49%, suggesting challenges in converting revenue into profit. The EBIT and EBITDA margins have improved, reflecting better operational efficiency, but still indicate room for growth.

Balance Sheet

The company's debt-to-equity ratio has improved significantly to 0.05, indicating a strong reduction in leverage and a more stable financial position. Return on equity has increased to 3.98%, showing improved profitability relative to shareholder equity. The equity ratio stands at 81.57%, reflecting a solid capital structure with a high proportion of equity financing.

Cash Flow

Free cash flow growth has been impressive at 99.15%, indicating strong cash generation capabilities. The operating cash flow to net income ratio of 0.49 suggests that the company is generating healthy cash flows relative to its net income. The free cash flow to net income ratio of 0.91 further supports the company's strong cash flow position.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	40.74M	54.35M	50.32M	50.67M	56.25M	63.56M
Gross Profit	5.21M	5.56M	3.88M	4.06M	6.55M	9.48M
EBITDA	2.93M	3.38M	1.47M	1.27M	3.56M	6.61M
Net Income	672.00K	808.00K	112.00K	-34.00K	3.84M	8.01M
Balance Sheet
Total Assets	25.54M	24.90M	26.21M	25.43M	25.25M	25.44M
Cash, Cash Equivalents and Short-Term Investments	4.73M	3.62M	1.68M	1.32M	331.00K	210.00K
Total Debt	761.00K	1.01M	1.80M	2.67M	2.06M	4.33M
Total Liabilities	5.05M	4.58M	6.97M	6.57M	6.67M	11.11M
Stockholders Equity	20.49M	20.32M	19.24M	18.86M	18.57M	14.33M
Cash Flow
Free Cash Flow	2.39M	1.87M	390.00K	1.12M	3.60M	2.75M
Operating Cash Flow	2.71M	2.06M	943.00K	1.23M	4.09M	3.05M
Investing Cash Flow	-322.00K	-205.00K	-553.00K	-111.00K	-465.00K	-199.00K
Financing Cash Flow	74.00K	78.00K	-29.00K	-136.00K	-3.50M	-3.04M

Integrated BioPharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBP, the sentiment is Positive. The current price of 0.34 is above the 20-day moving average (MA) of 0.34, above the 50-day MA of 0.32, and above the 200-day MA of 0.30, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 61.64 is Neutral, neither overbought nor oversold. The STOCH value of 56.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INBP.

Integrated BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INBP	66 Neutral	$11.38M	17.26	3.36%	―	4.72%	55.24%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
FTLF	55 Neutral	$143.21M	21.92	17.77%	―	12.44%	-20.33%
BON	52 Neutral	$12.16M	0.57	1.32%	―	-15.44%	-94.04%
NAII	48 Neutral	$29.34M	-2.43	-15.93%	―	18.19%	-35.22%
SOWG	45 Neutral	$9.66M	-0.42	-84.22%	―	-81.88%	-672.01%
HCWC	40 Underperform	$5.47M	―	―	―	―	―

Integrated BioPharma Corporate Events

Integrated BioPharma Holds 2025 Annual Stockholder Meeting

On December 1, 2025, Integrated BioPharma, Inc. held its 2025 Annual Meeting of Stockholders, where 22,651,488 shares were represented, forming a quorum. The stockholders voted on four proposals, including the election of Eric Friedman as Class III director, a non-binding advisory vote on executive compensation frequency, approval of executive compensation, and ratification of CBIZ CPAs P.C. as independent auditors for the fiscal year ending June 30, 2026.

The most recent analyst rating on (INBP) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Integrated BioPharma stock, see the INBP Stock Forecast page.